THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 16 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $35,751,000 | +11.0% | 38,442,000 | +13.7% | 1.43% | +42.4% |
| Q1 2022 | $32,208,000 | -1.3% | 33,824,000 | 0.0% | 1.00% | -1.2% |
| Q4 2021 | $32,640,000 | +4.7% | 33,824,000 | 0.0% | 1.01% | +9.0% |
| Q3 2021 | $31,165,000 | +353.8% | 33,824,000 | +338.0% | 0.93% | +302.6% |
| Q3 2020 | $6,867,000 | -10.1% | 7,723,000 | 0.0% | 0.23% | -17.2% |
| Q2 2020 | $7,636,000 | +65.7% | 7,723,000 | +63.5% | 0.28% | +24.0% |
| Q1 2020 | $4,609,000 | -79.0% | 4,723,000 | -77.7% | 0.22% | -77.2% |
| Q4 2019 | $21,949,000 | +11.5% | 21,223,000 | 0.0% | 0.99% | -26.2% |
| Q3 2019 | $19,693,000 | +97.8% | 21,223,000 | 0.0% | 1.34% | +58.1% |
| Q2 2019 | $9,955,000 | -52.1% | 21,223,000 | 0.0% | 0.85% | -53.0% |
| Q1 2019 | $20,803,000 | -5.1% | 21,223,000 | -0.2% | 1.80% | -34.0% |
| Q4 2018 | $21,929,000 | – | 21,273,000 | – | 2.73% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| LINDEN ADVISORS LP | 71,957,000 | $88,374,000 | 3.14% |
| Context Capital Management, LLC | 3,500,000 | $4,288,000 | 2.87% |
| Mohican Financial Management, LLC | 1,000,000 | $1,250,000 | 2.40% |
| Verition Fund Management LLC | 8,000,000 | $9,835,000 | 0.79% |
| ZAZOVE ASSOCIATES LLC | 8,170,000 | $10,024,000 | 0.51% |
| Baupost Group | 30,000,000 | $37,125,000 | 0.46% |
| WOLVERINE ASSET MANAGEMENT LLC | 24,020,000 | $29,431,000 | 0.33% |
| SSI INVESTMENT MANAGEMENT LLC | 3,007,000 | $3,683,000 | 0.31% |
| CSS LLC/IL | 2,900,000 | $3,556,000 | 0.17% |
| Rock Springs Capital Management LP | 1,500,000 | $1,844,000 | 0.08% |